Explore our interactive infographic to find out what you need to consider for each phase of development and get one step ahead with your molecule.
Discover how CatSci rapidly developed a robust and inherently safe process which enabled our customer to support their early clinical supply without surprises or delays.
Org. Process Res. Dev. 2022
Org. Process Res. Dev. 2022, 26, 5, 1398–1404
Org. Process Res. Dev. 2022, 26, 5, 1458–1469
General points to consider on solvent selection for scale-up
Access the recordings of our 10-year anniversary symposium now. The event was centred on the future of medicines development and featured industry-leading speakers from AstraZeneca, Bristol Myers Squibb, DeepMatter, FogPharma, Merck, Novartis, R.I, Roche, Syngenta, and more.
Understanding their common decomposition pathways
Our CCO, Dr Simon Tyler, argues that to achieve true sustainability, a more holistic approach to overall drug development is needed.
CatSci's analytical team facilitated the development and deployment of an efficient and fast UHPLC method screening protocol.
Solvent Selection Considerations
The broader suite of computer-aided synthesis planning tools is increasingly catching up with chemists in its ability to establish the most suitable way of putting together a target active pharmaceutical ingredient.
Access the recordings of our second virtual symposium now. The event featured an impressive itinerary of three eminent speakers from industry, who delivered digestible 30-minute presentations, covering topics from high throughput experimentation in organic synthesis to separation technology and analytical science.
Development of a flow scavenging protocol
Dr Alan Steven explains why environmental sustainability and “big picture thinking” should be key considerations when selecting solvents for scale-up.
CatSci was tasked with designing a new bromination method for a key reaction intermediate. Use of bromine rendered the previous process unsuitable for a larger campaign and would require expensive and time-consuming alterations to the plant.
The route supplied by the client involved the use of phenyl cyanate for functionalising a heterocyclic intermediate with a nitrile group. Its ongoing use would require cyanide monitoring, a dedicated waste stream treatment step, and there were concerns over the sourcing of material of appropriate quality over the long term.
The client's Phase 1 process was struggling to deliver API in low kg qualities. In particular, Intermediate B was of variable quality, and residual metals were known to negatively affect the onward chemistry.
CatSci was tasked with designing a new bromination method for a key reaction intermediate. Use of bromine rendered the previous process unsuitable for a larger campaign and would require expensive and time-consuming alterations to the plant.
CatSci was tasked with performing route-scouting, route selection and early-phase process development over a 6-month period to meet a pilot plant manufacturing slot.
CatSci was tasked with the development of a regioselective Buchwald-Hartwig amination for the final bond forming step of an API. The inherited conditions were not robust with respect to reaction conversion leading to stability concerns.